Allergan obtains patent: “Ophthalmic compositions and methods for treating eyes”

June 6, 2017: Allergan, Inc. of Irvine, CA, obtained U.S. Patent No. 9,668,997, “Ophthalmic compositions and methods for treating eyes”.

According to the abstract of the patent:

Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09668997.